Literature DB >> 26673812

Ibrutinib--a new standard treatment for relapsed mantle cell lymphoma?

Peter Martin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26673812     DOI： 10.1016/S0140-6736(15)01040-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.

Authors:  Jimmy Lee; Liang Leo Zhang; Wenjun Wu; Hui Guo; Yan Li; Madina Sukhanova; Girish Venkataraman; Shengjian Huang; Hui Zhang; Mir Alikhan; Pin Lu; Ailin Guo; Natalie Galanina; Jorge Andrade; Michael L Wang; Y Lynn Wang
Journal:  Blood Adv       Date:  2018-08-28

2.  Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

Authors:  Shyril O'Steen; Damian J Green; Ajay K Gopal; Johnnie J Orozco; Aimee L Kenoyer; Yukang Lin; D Scott Wilbur; Donald K Hamlin; Darrell R Fisher; Mark D Hylarides; Theodore A Gooley; Amelia Waltman; Brian G Till; Oliver W Press
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

3.  Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.

Authors:  Hui Guo; Dongfeng Zeng; Hui Zhang; Taylor Bell; Jun Yao; Yang Liu; Shengjian Huang; Carrie J Li; Elizabeth Lorence; Shouhao Zhou; Tiejun Gong; Changying Jiang; Makhdum Ahmed; Yixin Yao; Krystle J Nomie; Liang Zhang; Michael Wang
Journal:  Oncogene       Date:  2018-10-25       Impact factor: 9.867

Review 4.  The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.

Authors:  Haoran Wang; Wentao Zhang; Jingyi Yang; Keshu Zhou
Journal:  Hematol Oncol       Date:  2021-10-15       Impact factor: 4.850

5.  Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year.

Authors:  Carmen Herrero-Vicent; Isidro Machado; Carmen Illueca; Amparo Avaria; Claudia Salazar; Abraham Hernandez; Sergio Sandiego; Javier Lavernia
Journal:  Ecancermedicalscience       Date:  2016-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.